As COVID-19 ravaged the United States, a major biotechnology firm's annual convention in late February 2020 significantly fueled its spread across multiple states.
Reports confirm the U.S. saw its first COVID-19 cases from Europe, not Asia, in February. Tracing the virus's path offers critical insights into its rapid dissemination.
A New York Times article from April 12, 2020, highlights how Biogen, a leading biotechnology company, played a key role in seeding the virus domestically. The firm hosted its annual congress at the end of February, drawing 175 participants from across the United States.
Held over two days at Boston's Marriott Long Wharf Hotel, the gathering featured shared meals amid a festive vibe, with abundant handshakes and hugs. Biogen was riding high on breakthroughs in an Alzheimer's drug, and European collaborators joined the celebration.
Attendees soon scattered to at least six U.S. states—including Indiana, Tennessee, and North Carolina—plus countries like Austria, Germany, Argentina, and Norway. Six weeks on, Massachusetts tallied 99 cases among Biogen staff and families, with 70 of the first 92 state cases traced directly to the conference.
Critics argue Biogen should have canceled, especially with Europe's outbreak underway. Handshakes waned on day two, but the damage was done.
Biogen has since stepped up: donating $10 million for testing kits, supplying equipment and meals to frontline workers, and partnering with Vir Biotechnology on potential treatments.
